RxDoctor Payments Data

Anu Khatri, DO

Neurology · Bensalem, PANPI 1760406235

Payments from drug & device makers

$56,019in general payments, 2019–2025

Across 523 payments — averaging $107.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$50K
  • Lilly USA, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$949
  • Pfizer$840
  • UCB, Inc.$703
  • Amgen$413
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$45,55981%
  • Travel & lodging$1,5793%
  • Food & beverage$8,88116%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,019 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$11,219
Medicare patients
49
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant23$35,922
QuliptaAtogepant28$29,697
Nurtec OdtRimegepant Sulfate12$22,457
Emgality PenGalcanezumab-Gnlm18$14,591
XareltoRivaroxaban14$11,918
OzempicSemaglutide11$8,999
Carbidopa-Levodopa ErCarbidopa/Levodopa27$2,773
Sumatriptan Succinate12$1,153
Rosuvastatin Calcium48$1,097
Ezetimibe30$1,061
Atorvastatin Calcium73$877
Gabapentin33$861
Ropinirole Hcl21$539
Oxcarbazepine11$521
Losartan Potassium23$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$50,131$65,61951 claims
PfizerNurtec Odt$840$22,45712 claims
Novo NordiskOzempic$81$8,99911 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$191$37641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Bensalem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →